Comprehensive Clinical Trial Data Summation for BRAF‐MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma

由 Luke, Jason J.
發表在 Oncologist (2019)

Considering adjuvant therapy for stage II melanoma

由 Poklepovic, Andrew S., Luke, Jason J.
發表在 Cancer (2019)

Dendritic cells, the T cell-inflamed tumor microenvironment and immunotherapy treatment response

由 Garris, Christopher S., Luke, Jason J.
發表在 Clin Cancer Res (2020)

Improving Quality and Addressing the Rising Costs of Cancer Care: Two Birds, One Stone

由 Luke, Jason, Mirkin, Joshua, Bach, Peter
出版 2011

Chemotherapy in the Management of Advanced Cutaneous Malignant Melanoma

由 Luke, Jason J., Schwartz, Gary K.
出版 2013

Advances in the Systemic Treatment of Cutaneous Sarcomas

由 Luke, Jason J, Keohan, Mary-Louise
出版 2012

Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma

由 Luke, Jason J., Hodi, F. Stephen
出版 2013

New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy

由 Luke, Jason J, Ott, Patrick A
出版 2014

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma

由 Luke, Jason J., Ott, Patrick A.
發表在 Oncotarget (2015)

Mechanistic and pharmacologic insights on immune checkpoint inhibitors

由 Sweis, Randy F., Luke, Jason J.
發表在 Pharmacol Res (2017)

The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development

由 Olson, Daniel J, Luke, Jason J
發表在 Immunotherapy (2019)

Improving therapy in metastatic uveal melanoma by understanding prior failures

由 Olson, Daniel J., Luke, Jason J.
發表在 Oncoscience (2020)

Toll-Like Receptor 9 Agonists in Cancer

由 Karapetyan, Lilit, Luke, Jason J, Davar, Diwakar
發表在 Onco Targets Ther (2020)

Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types

由 Bao, Riyue, Stapor, Daniel, Luke, Jason J.
發表在 Genome Med (2020)

Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis

由 Labadie, Brian W., Bao, Riyue, Luke, Jason J.
發表在 Clin Cancer Res (2018)

PD-1 Blockade in Chinese versus Western Patients with Melanoma

由 Shoushtari, Alexander N., Bao, Riyue, Luke, Jason J.
發表在 Clin Cancer Res (2020)

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy

由 Trojaniello, Claudia, Luke, Jason J., Ascierto, Paolo A.
發表在 Front Oncol (2021)

ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19

由 Bao, Riyue, Hernandez, Kyle, Huang, Lei, Luke, Jason John
發表在 J Immunother Cancer (2020)

Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a ran...

由 Luke, Jason J., Zha, Yuanyuan, Matijevich, Karen, Gajewski, Thomas F.
發表在 J Immunother Cancer (2016)

High Throughput Multi-Omics Approaches for Clinical Trial Evaluation and Drug Discovery

由 Zielinski, Jessica M., Luke, Jason J., Guglietta, Silvia, Krieg, Carsten
發表在 Front Immunol (2021)